Go Pro

Amgen (AMGN) 10K Form and Latest SEC Filings 2026

Amgen logo
$390.74 -2.43 (-0.62%)
As of 01:33 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Latest Amgen SEC Filings & Recent Activity

Amgen (NASDAQ:AMGN) has submitted 917+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Amgen's financial statements. The most recent filing was a Form 3 submitted on September 4, 2026.

Form 4
AMGEN INC Reports Ownership Change on Aug. 13, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Amgen Files Current Report on Aug. 4, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Amgen SEC Filing History

Browse Amgen's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
09/04/2026 5:52 PM
Amgen (318154) Issuer
Dittrich Thomas J.W. (1491654) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/13/2026 6:05 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/13/2026 10:14 AM
Amgen (318154) Subject
Khosla Rachna (1881332) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/12/2026 7:04 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/11/2026 2:40 PM
Amgen (318154) Subject
Khosla Rachna (1881332) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/10/2026 7:24 PM
Amgen (318154) Issuer
ISHRAK OMAR (1523102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 7:20 PM
Amgen (318154) Issuer
Drake Michael V (1938942) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/10/2026 7:22 PM
Amgen (318154) Issuer
HOLLEY CHARLES M (1216478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 5:45 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/07/2026 5:47 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/06/2026 4:09 PM
Amgen (318154) Subject
Miller Derek (1917312) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/06/2026 2:17 PM
Amgen (318154) Subject
Grygiel Nancy A. (1816414) Reporting
Form 144/A
08/06/2026 1:13 PM
Amgen (318154) Subject
Grygiel Nancy A. (1816414) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
08/04/2026 3:03 PM
Amgen (318154) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/31/2026 3:03 PM
Amgen (318154) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/11/2026 3:22 PM
Amgen (318154) Filer
Form 11-K
Annual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)  
05/21/2026 6:08 PM
Amgen (318154) Issuer
MILES AMY E (1248617) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 5:54 PM
Amgen (318154) Issuer
Austin Wanda M (1690882) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 5:56 PM
Amgen (318154) Issuer
Drake Michael V (1938942) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 5:57 PM
Amgen (318154) Issuer
Druker Brian (1740205) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 5:58 PM
Amgen (318154) Issuer
ECKERT ROBERT (1194256) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 5:59 PM
Amgen (318154) Issuer
Garland Greg C. (1503107) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 6:01 PM
Amgen (318154) Issuer
HOLLEY CHARLES M (1216478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 6:02 PM
Amgen (318154) Issuer
ISHRAK OMAR (1523102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 6:04 PM
Amgen (318154) Issuer
Jacks Tyler (1464237) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 6:05 PM
Amgen (318154) Issuer
Klotman Mary E. (2020575) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/21/2026 6:07 PM
Amgen (318154) Issuer
Kullman Ellen Jamison (1303141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/20/2026 3:59 PM
Amgen (318154) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/14/2026 12:55 PM
Amgen (318154) Subject
Capital World Investors (1422849) Filed by
Form SCHEDULE 13G
05/11/2026 7:07 PM
Amgen (318154) Issuer
REESE DAVID M (1748434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:15 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:17 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 6:58 PM
Amgen (318154) Issuer
Gordon Murdo (1642156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:00 PM
Amgen (318154) Issuer
Graham Jonathan P (1365306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:01 PM
Amgen (318154) Issuer
Griffith Peter H. (1798821) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:02 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:04 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 7:06 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 6:39 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/11/2026 6:36 PM
Amgen (318154) Issuer
Bradner James E. (2005159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 8:12 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
Your $29.97 book is free today (Ad)

Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.tc pixel

Normally $29.97. Today it's free. Grab your copy now.
05/07/2026 8:14 PM
Amgen (318154) Issuer
Bradner James E. (2005159) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:52 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:54 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:56 PM
Amgen (318154) Issuer
Griffith Peter H. (1798821) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:59 PM
Amgen (318154) Issuer
Graham Jonathan P (1365306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 8:01 PM
Amgen (318154) Issuer
Gordon Murdo (1642156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 8:06 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:38 PM
Amgen (318154) Issuer
HOLLEY CHARLES M (1216478) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:40 PM
Amgen (318154) Issuer
ISHRAK OMAR (1523102) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:46 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:48 PM
Amgen (318154) Issuer
REESE DAVID M (1748434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:50 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 7:36 PM
Amgen (318154) Issuer
Drake Michael V (1938942) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:06 PM
Amgen (318154) Issuer
Gordon Murdo (1642156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:07 PM
Amgen (318154) Issuer
Graham Jonathan P (1365306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:08 PM
Amgen (318154) Issuer
Griffith Peter H. (1798821) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:09 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:11 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:11 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:12 PM
Amgen (318154) Issuer
REESE DAVID M (1748434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:13 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 6:52 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/05/2026 7:05 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/04/2026 3:05 PM
Amgen (318154) Subject
Grygiel Nancy A. (1816414) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
04/22/2026 3:03 PM
Amgen (318154) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/21/2026 4:00 PM
Amgen (318154) Filer
Form DEFA14A
04/15/2026 3:15 PM
Amgen (318154) Filer
Form DEFA14A
04/07/2026 3:25 PM
Amgen (318154) Filer
Form DEFA14A
04/07/2026 3:22 PM
Amgen (318154) Filer
Form DEF 14A
03/31/2026 8:00 AM
Amgen (318154) Filer
Form ARS
03/26/2026 2:43 PM
Amgen (318154) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/18/2026 7:37 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:38 PM
Amgen (318154) Issuer
REESE DAVID M (1748434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:39 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:26 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:28 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:30 PM
Amgen (318154) Issuer
Gordon Murdo (1642156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:31 PM
Amgen (318154) Issuer
Graham Jonathan P (1365306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:32 PM
Amgen (318154) Issuer
Griffith Peter H. (1798821) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:34 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/18/2026 7:36 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/06/2026 6:32 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:41 PM
Amgen (318154) Issuer
Miller Derek (1917312) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:42 PM
Amgen (318154) Issuer
REESE DAVID M (1748434) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:43 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:37 PM
Amgen (318154) Issuer
Griffith Peter H. (1798821) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:38 PM
Amgen (318154) Issuer
Grygiel Nancy A. (1816414) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:39 PM
Amgen (318154) Issuer
Khosla Rachna (1881332) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:16 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:19 PM
Amgen (318154) Issuer
Bradway Robert A (1396482) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad)

The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel

03/05/2026 7:20 PM
Amgen (318154) Issuer
Gordon Murdo (1642156) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/05/2026 7:22 PM
Amgen (318154) Issuer
Graham Jonathan P (1365306) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/02/2026 6:20 PM
Amgen (318154) Issuer
Santos Esteban (1677950) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/27/2026 11:20 AM
Amgen (318154) Subject
Santos Esteban (1677950) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/24/2026 3:30 PM
Amgen (318154) Subject
Nasdaq Stock Market LLC (1354457) Filed by
Form 25-NSE
02/20/2026 6:43 PM
Amgen (318154) Issuer
Busch Matthew C. (1987926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/19/2026 2:55 PM
Amgen (318154) Subject
Busch Matthew C. (1987926) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
02/18/2026 8:06 PM
Amgen (318154) Filer
Form 424B2
Transaction specifc information for a delayed shelf offering
02/17/2026 7:33 AM
Amgen (318154) Filer
Form 424B3
(Data available from 1/1/2016 forward)

Amgen SEC Filings - Frequently Asked Questions

Amgen (AMGN) has submitted 917+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Amgen's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Amgen's financial statements page.

The most recent filing was a Form 3 submitted on September 4, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:AMGN are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 9/4/2026. New filings are added as they're published.
From Our Partners